Published in Imaging Med on February 01, 2014
Ultrasound imaging of breast tumor perfusion and neovascular morphology. Ultrasound Med Biol (2015) 0.79
Molecular Ultrasound Imaging of Tissue Inflammation Using an Animal Model of Acute Kidney Injury. Mol Imaging Biol (2015) 0.76
Monitoring of Blood Vessel Density Using Contrast-Enhanced High Frequency Ultrasound May Facilitate Early Diagnosis of Lymph Node Metastasis. J Cancer (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med (1995) 26.60
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med (1991) 19.46
The biology of vascular endothelial growth factor. Endocr Rev (1997) 13.70
What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst (1990) 13.41
Tumorigenesis and the angiogenic switch. Nat Rev Cancer (2003) 11.95
Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst (1992) 8.69
Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation (1998) 5.93
Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol (2013) 4.23
Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev (2005) 3.38
Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation (2003) 3.15
US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology (2008) 3.15
Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to alpha(v)-integrins. Circulation (2003) 2.67
Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). Radiology (2010) 2.32
Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res (2007) 2.19
Bioeffects considerations for diagnostic ultrasound contrast agents. J Ultrasound Med (2008) 2.16
Quantitative angiogenesis assays: progress and problems. Nat Med (1997) 2.10
Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology (2008) 1.88
Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic micro-PET in mice. Radiology (2008) 1.88
Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol (1995) 1.81
Ultrasound contrast agents: properties, principles of action, tolerance, and artifacts. Eur Radiol (2001) 1.80
Influence of lipid shell physicochemical properties on ultrasound-induced microbubble destruction. IEEE Trans Ultrason Ferroelectr Freq Control (2005) 1.77
Oncotic pressure in solid tumors is elevated. Cancer Res (2000) 1.69
Ultrasound molecular imaging of tumor angiogenesis with an integrin targeted microbubble contrast agent. Invest Radiol (2011) 1.64
BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis. Invest Radiol (2010) 1.62
Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging. Radiology (2011) 1.61
Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects. Mol Cancer Ther (2008) 1.58
Quantitative volumetric perfusion mapping of the microvasculature using contrast ultrasound. Invest Radiol (2010) 1.54
Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results. Radiology (2010) 1.51
Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res (2010) 1.42
Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer Res (2011) 1.40
Molecular imaging of vascular endothelial growth factor receptor 2 expression using targeted contrast-enhanced high-frequency ultrasonography. J Ultrasound Med (2007) 1.38
Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: a new diagnostic tool to evaluate the early effects of antiangiogenic treatment. Eur Radiol (2007) 1.38
scVEGF microbubble ultrasound contrast agents: a novel probe for ultrasound molecular imaging of tumor angiogenesis. Invest Radiol (2010) 1.35
Selective imaging of adherent targeted ultrasound contrast agents. Phys Med Biol (2007) 1.31
An EFSUMB introduction into Dynamic Contrast-Enhanced Ultrasound (DCE-US) for quantification of tumour perfusion. Ultraschall Med (2012) 1.29
Evaluation of tumor angiogenesis with US: imaging, Doppler, and contrast agents. Acad Radiol (2000) 1.28
Preparation of targeted microbubbles: ultrasound contrast agents for molecular imaging. Med Biol Eng Comput (2009) 1.20
Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. AJR Am J Roentgenol (2006) 1.20
A triple-targeted ultrasound contrast agent provides improved localization to tumor vasculature. J Ultrasound Med (2011) 1.19
Contrast-enhanced computed tomography and ultrasound for the evaluation of tumor blood flow. Invest Radiol (2005) 1.17
Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55. Invest Radiol (2010) 1.17
Multimodality molecular imaging of CD105 (Endoglin) expression. Int J Clin Exp Med (2010) 1.16
A new formalism for the quantification of tissue perfusion by the destruction-replenishment method in contrast ultrasound imaging. IEEE Trans Ultrason Ferroelectr Freq Control (2006) 1.15
Response evaluation of chemotherapy in metastatic colorectal cancer by contrast enhanced ultrasound. World J Gastroenterol (2012) 1.15
Contrast-enhanced ultrasound is helpful in the differentiation of malignant and benign breast lesions. Eur J Radiol (2009) 1.14
Dual frequency method for simultaneous translation and real-time imaging of ultrasound contrast agents within large blood vessels. Ultrasound Med Biol (2009) 1.14
P-selectin cell adhesion molecule in inflammation, thrombosis, cancer growth and metastasis. Curr Med Chem (2004) 1.14
Contrast-enhanced ultrasonography better identifies pancreatic tumor vascularization than helical CT. Pancreatology (2005) 1.13
Molecular and functional ultrasound imaging in differently aggressive breast cancer xenografts using two novel ultrasound contrast agents (BR55 and BR38). Eur Radiol (2011) 1.11
Quantitative mapping of tumor vascularity using volumetric contrast-enhanced ultrasound. Invest Radiol (2012) 1.11
Determination of breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound and artificial neural networks. J Ultrasound Med (2010) 1.11
Assessment of molecular imaging of angiogenesis with three-dimensional ultrasonography. Mol Imaging (2011) 1.11
Microbubbles as ultrasound contrast agents for molecular imaging: preparation and application. AJR Am J Roentgenol (2012) 1.11
Mapping microvasculature with acoustic angiography yields quantifiable differences between healthy and tumor-bearing tissue volumes in a rodent model. Radiology (2012) 1.10
Parametric imaging using subharmonic signals from ultrasound contrast agents in patients with breast lesions. J Ultrasound Med (2011) 1.07
A method for differentiating targeted microbubbles in real time using subharmonic micro-ultrasound and interframe filtering. Ultrasound Med Biol (2009) 1.07
Microbubble-mediated ultrasonic techniques for improved chemotherapeutic delivery in cancer. J Drug Target (2011) 1.07
Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy. Ultrasound Med Biol (2012) 1.05
The high angiogenic activity in very early breast cancer enables reliable imaging with VEGFR2-targeted microbubbles (BR55). Eur Radiol (2012) 1.04
Tumour angiogenesis. J Pathol (1983) 1.03
Angiogenesis: noninvasive quantitative assessment with contrast-enhanced functional US in murine model. Radiology (2006) 1.02
Indicator dilution models for the quantification of microvascular blood flow with bolus administration of ultrasound contrast agents. IEEE Trans Ultrason Ferroelectr Freq Control (2010) 1.02
Molecular ultrasound imaging using a targeted contrast agent for assessing early tumor response to antiangiogenic therapy. J Ultrasound Med (2012) 1.01
Successful left ventricular opacification following peripheral venous injection of sonicated contrast agent: an experimental evaluation. Am Heart J (1987) 1.01
Standardization of dynamic contrast-enhanced ultrasound for the evaluation of antiangiogenic therapies: the French multicenter Support for Innovative and Expensive Techniques Study. Invest Radiol (2012) 0.99
Real-time technique for improving molecular imaging and guiding drug delivery in large blood vessels: in vitro and ex vivo results. Mol Imaging (2011) 0.98
Quantification of flow using ultrasound and microbubbles: a disruption replenishment model based on physical principles. Ultrasound Med Biol (2009) 0.97
Contrast-enhanced ultrasound for molecular imaging of angiogenesis. Eur J Nucl Med Mol Imaging (2010) 0.97
A sensitive TLRH targeted imaging technique for ultrasonic molecular imaging. IEEE Trans Ultrason Ferroelectr Freq Control (2010) 0.96
Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody. Br J Cancer (1996) 0.96
Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res (2005) 0.95
Application of molecular ultrasound for imaging integrin expression. Theranostics (2011) 0.94
Function and antagonism of beta3 integrins in the development of cancer therapy. Curr Cancer Drug Targets (2009) 0.93
Three-dimensional subharmonic ultrasound imaging in vitro and in vivo. Acad Radiol (2012) 0.93
Breast tumor vascularity identified by contrast enhanced ultrasound and pathology: initial results. Ultrasonics (2000) 0.93
Correlation of quantified contrast-enhanced sonography with in vivo tumor response. J Ultrasound Med (2010) 0.92
Ultrasound is now better than mammography for the detection of invasive breast cancer. Am J Surg (2004) 0.92
Arterial-phase contrast-enhanced ultrasonography for evaluating anti-angiogenesis treatment: a pilot study. World J Gastroenterol (2011) 0.91
Molecular ultrasound imaging of early vascular response in prostate tumors irradiated with carbon ions. Neoplasia (2009) 0.91
Sonographic depiction of tumor vascularity and flow: from in vivo models to clinical applications. J Ultrasound Med (2000) 0.90
Effects of acoustic radiation force on the binding efficiency of BR55, a VEGFR2-specific ultrasound contrast agent. Ultrasound Med Biol (2012) 0.89
Ultrasound molecular imaging of E-selectin in tumor vessels using poly n-butyl cyanoacrylate microbubbles covalently coupled to a short targeting peptide. Invest Radiol (2013) 0.88
Molecular targeting of ultrasonographic contrast agent for detection of head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (2012) 0.88
Angiogenesis model for ultrasound contrast research: exploratory study. Acad Radiol (2004) 0.88
[Evaluation of early response to antiangiogenic treatment with dynamic contrast enhanced ultrasound]. J Radiol (2008) 0.87
VEGF-VEGF receptor complexes as markers of tumor vascular endothelium. J Control Release (2001) 0.86
Contrast enhanced maximum intensity projection ultrasound imaging for assessing angiogenesis in murine glioma and breast tumor models: A comparative study. Ultrasonics (2010) 0.86
Contrast-ultrasound dispersion imaging for prostate cancer localization by improved spatiotemporal similarity analysis. Ultrasound Med Biol (2013) 0.86
Optical fluorescent imaging to monitor temporal effects of microbubble-mediated ultrasound therapy. IEEE Trans Ultrason Ferroelectr Freq Control (2013) 0.85
Perfusion estimation using contrast-enhanced 3-dimensional subharmonic ultrasound imaging: an in vivo study. Invest Radiol (2013) 0.85
Liver dysplasia: US molecular imaging with targeted contrast agent enables early assessment. Radiology (2013) 0.84
Quantitative morphometric analysis of the microcirculation in prostate carcinoma. J Cell Biochem Suppl (1992) 0.84
Quantitative contrast-enhanced ultrasound for imaging antiangiogenic treatment response in experimental osteolytic breast cancer bone metastases. Invest Radiol (2012) 0.83
Microbubble therapy enhances anti-tumor properties of cisplatin and cetuximab in vitro and in vivo. Otolaryngol Head Neck Surg (2012) 0.83
Comparing contrast-enhanced color flow imaging and pathological measures of breast lesion vascularity. Ultrasound Med Biol (2008) 0.82
Delta-projection imaging on contrast-enhanced ultrasound to quantify tumor microvasculature and perfusion. Acad Radiol (2009) 0.82
Model system using controlled receptor expression for evaluating targeted ultrasound contrast agents. Ultrasound Med Biol (2011) 0.82
Volumetric contrast-enhanced ultrasound imaging to assess early response to apoptosis-inducing anti-death receptor 5 antibody therapy in a breast cancer animal model. J Ultrasound Med (2012) 0.81